AzTrials
AzTrials

Neurogenic Detrusor OveractivityPhase 3NCT01981954

A Clinical Study to Investigate How Solifenacin Fluid is Taken up, How Long it Stays in the Body and How Effective and Safe it is in Treating Children Aged From 6 Months to Less Than 5 Years With Symptoms of Neurogenic Detrusor Overactivity (NDO)

A Phase 3 study testing Solifenacin succinate in people with Neurogenic Detrusor Overactivity and Pediatric, run by Astellas Pharma Europe B.V. at 8 sites in 6 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study was to evaluate long term efficacy and safety of treatment with solifenacin succinate (the study drug) in children with neurogenic detrusor overactivity after multiple dose administration. Read more about this study

Who is it for?
Ages 6 months to 4 years
Conditions the study is for
Neurogenic Detrusor Overactivity, Pediatric
What is being tested?
Solifenacin succinate
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
23 participants
Where
8 sitesin 6 countries
Study dates
25 Sep 2013to 18 Dec 2015
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 6 months to 4 years
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • Myelomeningocoele
  • Documented diagnosis of NDO, confirmed by urodynamics
  • DSD (detrusor sphincter dyssynergia)
  • Practicing clean intermittent catheterization (CIC)

Who cannot join

  • Know genitourinary condition (other than NDO) that may cause incontinence
  • Bladder augmentation surgery
  • Current faecal impaction
  • Electro-stimulation therapy within 2 weeks prior to visit
  • Subjects with the following gastro-intestinal problems: partial or complete obstructions, decreased motility like paralytic ileus, subjects at risk of gastric retention
  • Reflux grade 3 to 5
  • Current urinary tract infection

Trial locations and contacts

8 sites in 6 countries.

8 sites in 6 countries

Poland2 sites
  • Site PL4803 Uniwersyteckie Centrum Kliniczne

    Gdansk, 81-211

  • Site PL4801 Pomnik-Centrum Zdrowia Dziecka

    Warsaw, 04-730

Other trials in Poland

South Korea2 sites
  • Site KR8207 Seoul National University Hospital

    Seoul, 110744

  • Site KR8201 Severance Hospital

    Seoul, 120752

Other trials in South Korea

United States1 site
  • Site US1008 Pediatric Urology Associates, P.C.

    Tarrytown, New York, 10591

Other trials in United States

Belgium1 site
  • Site BE3203 Gent University Hospital

    Ghent, 9000

Other trials in Belgium

Philippines1 site
  • Site PH6301 Philippines Children's Medical Center

    Manila, 1015

Other trials in Philippines

United Kingdom1 site
  • Site GB4401 Sheffield Children's Hospital

    Sheffield, S10 2TN

Other trials in United Kingdom

About this study

Official title: A Phase 3, Open-Label, Baseline-controlled, Multi-center, Sequential Dose-Titration Study to Assess the Pharmacokinetics, Long-Term Efficacy and Safety of Solifenacin Succinate Suspension in Children From 6 Months to Less Than 5 Years of Age With Neurogenic Detrusor Overactivity

The purpose of this study was to evaluate long term efficacy and safety of treatment with solifenacin succinate (the study drug) in children with neurogenic detrusor overactivity after multiple dose administration.

Read the detailed description

In some children with a severe form of spina bifida (which is the consequence of a spinal cord defect), the bladder muscle (detrusor) contracts strongly and without warning (also known as neurogenic detrusor overactivity) and the urethra (the passage connecting the bladder with outside) does not relax. Though these children cannot void, urine leakage can happen when the overactive contractions are strong, and/or the pressure in the bladder is so high that it overcomes the closed urethra (overflow at high filling bladder pressure). This high bladder pressure puts these children at risk for kidney damage and can decrease the quality of the bladder. Therapy was aimed to decrease the high filling bladder pressure and the overactive detrusor contractions.

Being tested
Solifenacin succinate
Keywords
Solifenacin succinate suspension, Efficacy, Safety

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Solifenacin succinateDrug

    Also called solifenacin, YM905, solifenacin succinate suspension

    Oral suspension

Study groups in NCT01981954
Study groupRoleWhat they receive
Solifenacin succinateExperimentalChildren aged 6 months to less than 5 years were treated with sequential titrated doses of solifenacin up to 12 weeks in the Titration period after which a fixed dose of solifenacin was given for at least 40 weeks in the Fixed-dose assessment period. Children received solifenacin once daily during these 2 periods.
Receives: Drug: Solifenacin succinate

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change From Baseline to Week 24 in Maximum Cystometric Capacity (MCC)

    MCC was the volume instilled into the bladder prior to leakage or end of bladder-filling (whichever was reached first), as assessed by urodynamics (procedure: the bladder was to be filled until voiding/leakage began, or until it was stopped because either the participant experienced pain or discomfort or 135% of expected bladder capacity [EBC] was reached for participants ≥ 2 years or of maximum catheterized volume [MCV] for participants aged 6 months to < 2 years; the participants' bladder was emptied via catheterization).

    Measured: Baseline and Week 24

Secondary outcomes (41)
  1. Change From Baseline to Weeks 3, 6, 9, 12 and 52 in MCC

    MCC was the volume instilled into the bladder prior to leakage or end of bladder-filling (whichever was reached first) as assessed by urodynamics (procedure: the bladder was to be filled until voiding/leakage began, or until it was stopped because either the participant experienced pain or discomfort or 135% of EBC was reached for participants ≥ 2 years or of MCV for participants aged 6 months to < 2 years. The participants' bladder was emptied via catheterization).

    Measured: Baseline and Weeks 3, 6, 9, 12, 52

  2. Change From Baseline to Weeks 3, 6, 9, 12, 24 and 52 in Bladder Compliance

    Bladder compliance gives an indication of the elasticity of the bladder wall. Bladder compliance was calculated by dividing the change in volume during the filling of the bladder by the change in detrusor pressure during that change in bladder volume using urodynamic assessments. The values for bladder volume and detrusor pressure at the beginning and end of filling were taken and used.

    Measured: Baseline and Weeks 3, 6, 9, 12, 24, 52

  3. Change From Baseline to Weeks 3, 6, 9, 12, 24 and 52 in Detrusor Pressure at End of Bladder-Filling

    Detrusor pressure was expressed as bladder pressure minus intra-abdominal pressure as assessed by urodynamics.

    Measured: Baseline and Weeks 3, 6, 9, 12, 24, 52

  4. Change From Baseline to Weeks 3, 6, 9, 12, 24 and 52 in Detrusor Pressure 5 Minutes After End of Bladder-Filling

    Detrusor pressure was expressed as bladder pressure minus intra-abdominal pressure as assessed by urodynamics.

    Measured: Baseline and Weeks 3, 6, 9, 12, 24, 52

  5. Change From Baseline to Weeks 3, 6, 9, 12, 24 and 52 in Catheterized Volume 5 Minutes After End of Bladder-Filling

    Catheterized volume was measured when the bladder was emptied via catheterization 5 minutes after the end of bladder-filling.

    Measured: Baseline and Weeks 3, 6, 9, 12, 24, 52

  6. Change From Baseline to Weeks 3, 6, 9, 12, 24 and 52 in Bladder Volume Until First Detrusor Contraction (> 15 cmH2O)

    Bladder volume as assessed by urodynamics.

    Measured: Baseline and Weeks 3, 6, 9, 12, 24, 52

  7. Change From Baseline to Weeks 3, 6, 9, 12, 24 and 52 in Bladder Volume at 10 cmH20 Detrusor Pressure

    Bladder volume as assessed by urodynamics.

    Measured: Baseline and Weeks 3, 6, 9, 12, 24, 52

  8. Change From Baseline to Weeks 3, 6, 9, 12, 24 and 52 in Bladder Volume at 20 cmH20 Detrusor Pressure

    Bladder volume as assessed by urodynamics.

    Measured: Baseline and Weeks 3, 6, 9, 12, 24, 52

  9. Change From Baseline to Weeks 3, 6, 9, 12, 24 and 52 in Bladder Volume at 30 cmH20 Detrusor Pressure

    Bladder volume as assessed by urodynamics.

    Measured: Baseline and Weeks 3, 6, 9, 12, 24, 52

  10. Change From Baseline to Weeks 3, 6, 9, 12, 24 and 52 in Number of Overactive Detrusor Contractions (> 15 cmH2O) Until Leakage or End of Bladder-Filling

    Measured: Baseline and Weeks 3, 6, 9, 12, 24, 52

  11. Change From Baseline to Weeks 3, 6, 9, 12, 24, 36 and 52 in Average Catheterized Volume Per Catheterization

    The average catheterized volume per catheterization was calculated using all available (non-zero) catheterized volumes recorded over both of the 2 measuring days in the diary, whether or not these 2 days were concurrent. Catheterized volumes were recorded for 2 days in a participant diary prior to each visit. Four to six catheterizations were performed every day.

    Measured: Baseline and Weeks 3, 6, 9, 12, 24, 36, 52

  12. Change From Baseline to Weeks 3, 6, 9, 12, 24, 36 and 52 in Maximum Catheterized Volume (MCV)

    The maximum catheterized volume per day was calculated using all available (non-zero) catheterized volumes recorded for the 2 measuring days in the diary, whether or not these 2 days were concurrent. The maximum value was calculated separately for each measuring day and the mean of these two values was used.

    Measured: Baseline and Weeks 3, 6, 9, 12, 24, 36, 52

  13. Change From Baseline to Weeks 3, 6, 9, 12, 24, 36 and 52 in Average First Morning Catheterized Volume

    The first morning catheterized volume was the volume associated with the first morning catheterization. The average first morning catheterized volume was calculated as the average of the available first morning catheterized volumes recorded for the 2 measuring days in the diary, whether or not these 2 days are concurrent.

    Measured: Baseline and Weeks 3, 6, 9, 12, 24, 36, 52

  14. Change From Baseline to Weeks 3, 6, 9, 12, 24, 36 and 52 in Mean Number of Periods Between the Clean Intermittent Catheterizations (CICs) With Incontinence Per 24 Hours

    Participants were required to have 4-6 CICs per day on a schedule fixed for the duration of the study. To calculate the number of periods between CICs with incontinence in a diary day, the diary day was divided into periods between CICs (i.e. inter-CIC periods). The hour period, rather than the exact time, of each CIC and incontinence episode was recorded in the diary. When an incontinence episode and a CIC were marked in the same hour period, the incontinence episode was counted as occurring prior to the CIC (when the bladder had not yet emptied), rather than after it (when the bladder had recently been emptied), i.e. the inter-CIC period ended with the hour in which the CIC was recorded. The mean number of periods between CICs with incontinence per 24 hours was the number of periods between CICs when incontinence occurred, divided by the total number of valid diary days.

    Measured: Baseline and Weeks 3, 6, 9, 12, 24, 36, 52

  15. Percentage of Days With Catheterizations for Each Hour of 24 Hour Day at Baseline

    For each one hour period of the 24 hour day, the percentage of days with catheterization was assessed as the number of days with catheterization occurring within the one hour period divided by the number of valid diary days over all participants. Each participant contributed to up to three days of valid diary data for each visit.

    Measured: 3 days prior to Baseline visit

  16. Percentage of Days With Catheterizations for Each Hour of 24 Hour Day During Week 3

    For each one hour period of the 24 hour day, the percentage of days with catheterization was assessed as the number of days with catheterization occurring within the one hour period divided by the number of valid diary days over all participants. Each participant contributed to up to three days of valid diary data for each visit.

    Measured: 3 days prior to Week 3 visit

  17. Percentage of Days With Catheterizations for Each Hour of 24 Hour Day During Week 6

    For each one hour period of the 24 hour day, the percentage of days with catheterization was assessed as the number of days with catheterization occurring within the one hour period divided by the number of valid diary days over all participants. Each participant contributed to up to three days of valid diary data for each visit.

    Measured: 3 days prior to Week 6 visit

  18. Percentage of Days With Catheterizations for Each Hour of 24 Hour Day During Week 9

    For each one hour period of the 24 hour day, the percentage of days with catheterization was assessed as the number of days with catheterization occurring within the one hour period divided by the number of valid diary days over all participants. Each participant contributed to up to three days of valid diary data for each visit.

    Measured: 3 days prior to Week 9 visit

  19. Percentage of Days With Catheterizations for Each Hour of 24 Hour Day During Week 12

    For each one hour period of the 24 hour day, the percentage of days with catheterization was assessed as the number of days with catheterization occurring within the one hour period divided by the number of valid diary days over all participants. Each participant contributed to up to three days of valid diary data for each visit.

    Measured: 3 days prior to Week 12 visit

  20. Percentage of Days With Catheterizations for Each Hour of 24 Hour Day During Week 24

    For each one hour period of the 24 hour day, the percentage of days with catheterization was assessed as the number of days with catheterization occurring within the one hour period divided by the number of valid diary days over all participants. Each participant contributed to up to three days of valid diary data for each visit.

    Measured: 3 days prior to Week 24 visit

  21. Percentage of Days With Catheterizations for Each Hour of 24 Hour Day During Week 36

    For each one hour period of the 24 hour day, the percentage of days with catheterization was assessed as the number of days with catheterization occurring within the one hour period divided by the number of valid diary days over all participants. Each participant contributed to up to three days of valid diary data for each visit.

    Measured: 3 days prior to Week 36 visit

  22. Percentage of Days With Catheterizations for Each Hour of 24 Hour Day During Week 52

    For each one hour period of the 24 hour day, the percentage of days with catheterization was assessed as the number of days with catheterization occurring within the one hour period divided by the number of valid diary days over all subjects. Each participant contributed to up to three days of valid diary data for each visit.

    Measured: 3 days prior to Week 52 visit

  23. Percentage of Days With Incontinence for Each Hour of 24 Hour Day at Baseline

    Incontinence was defined as leakage where a diaper is not used, or dampness where a diaper is used. For each one hour period of the 24 hour day, the percentage of days with incontinence was assessed as the number of days with incontinence occurring within the one hour period divided by the number of valid diary days over all participants. Each participant contributed to up to three days of valid diary data for each visit.

    Measured: 3 days prior to Baseline visit

  24. Percentage of Days With of Incontinence for Each Hour of 24 Hour Day During Week 3

    Incontinence was defined as leakage where a diaper is not used, or dampness where a diaper is used. For each one hour period of the 24 hour day, the percentage of days with incontinence was assessed as the number of days with incontinence occurring within the one hour period divided by the number of valid diary days over all participants. Each participant contributed to up to three days of valid diary data for each visit.

    Measured: 3 days prior to Week 3 visit

  25. Percentage of Days With Incontinence for Each Hour of 24 Hour Day During Week 6

    Incontinence was defined as leakage where a diaper is not used, or dampness where a diaper is used. For each one hour period of the 24 hour day, the percentage of days with incontinence was assessed as the number of days with incontinence occurring within the one hour period divided by the number of valid diary days over all participants. Each participant contributed to up to three days of valid diary data for each visit.

    Measured: 3 days prior to Week 6 visit

  26. Percentage of Days With Incontinence for Each Hour of 24 Hour Day During Week 9

    Incontinence was defined as leakage where a diaper is not used, or dampness where a diaper is used. For each one hour period of the 24 hour day, the percentage of days with incontinence was assessed as the number of days with incontinence occurring within the one hour period divided by the number of valid diary days over all participants. Each participant contributed to up to three days of valid diary data for each visit.

    Measured: 3 days prior to Week 9 visit

  27. Percentage of Days With Incontinence for Each Hour of 24 Hour Day During Week 12

    Incontinence was defined as leakage where a diaper is not used, or dampness where a diaper is used. For each one hour period of the 24 hour day, the percentage of days with incontinence was assessed as the number of days with incontinence occurring within the one hour period divided by the number of valid diary days over all participants. Each participant contributed to up to three days of valid diary data for each visit.

    Measured: 3 days prior to Week 12 visit

  28. Percentage of Days With Incontinence for Each Hour of 24 Hour Day During Week 24

    Incontinence was defined as leakage where a diaper is not used, or dampness where a diaper is used. For each one hour period of the 24 hour day, the percentage of days with incontinence was assessed as the number of days with incontinence occurring within the one hour period divided by the number of valid diary days over all participants. Each participant contributed to up to three days of valid diary data for each visit.

    Measured: 3 days prior to Week 24 visit

  29. Percentage of Days With Incontinence for Each Hour of 24 Hour Day During Week 36

    Incontinence was defined as leakage where a diaper is not used, or dampness where a diaper is used. For each one hour period of the 24 hour day, the percentage of days with incontinence was assessed as the number of days with incontinence occurring within the one hour period divided by the number of valid diary days over all participants. Each participant contributed to up to three days of valid diary data for each visit.

    Measured: 3 days prior to Week 36 visit

  30. Percentage of Days With Incontinence for Each Hour of 24 Hour Day During Week 52

    Incontinence was defined as leakage where a diaper is not used, or dampness where a diaper is used. For each one hour period of the 24 hour day, the percentage of days with incontinence was assessed as the number of days with incontinence occurring within the one hour period divided by the number of valid diary days over all participants. Each participant contributed to up to three days of valid diary data for each visit.

    Measured: 3 days prior to Week 52 visit

  31. Change From Baseline to Week 24 and 52 in Infant and Toddler Quality of Life Short Form-47 Questionnaire (ITQoL SF-47) - Overall Health Score

    The ITQoL SF-47 consisted of 47 individual items and was filled in by the child's parent. The individual items are based on Likert scales with either 5 responses (coded as 1 through to 5) or 4 responses (coded as 1 through to 4). From subsets of these coded values, 11 scales are derived: overall health, physical activities, development, discomfort, moods and temperaments, perceptions of current past and future health and perception of changes. Each scale score ranges from 0 (worst possible) to 100 (best possible).

    Measured: Baseline and Weeks 24, 52

  32. Change From Baseline to Week 24 and 52 in ITQoL SF-47 - Physical Abilities Score

    The ITQoL SF-47 consisted of 47 individual items and was filled in by the child's parent. The individual items are based on Likert scales with either 5 responses (coded as 1 through to 5) or 4 responses (coded as 1 through to 4). From subsets of these coded values, 11 scales are derived: overall health, physical activities, development, discomfort, moods and temperaments, perceptions of current past and future health and perception of changes. Each scale score ranges from 0 (worst possible) to 100 (best possible).

    Measured: Baseline and Weeks 24, 52

  33. Change From Baseline to Week 24 and 52 in ITQoL SF-47 - Growth and Development Score

    The ITQoL SF-47 consisted of 47 individual items and was filled in by the child's parent. The individual items are based on Likert scales with either 5 responses (coded as 1 through to 5) or 4 responses (coded as 1 through to 4). From subsets of these coded values, 11 scales are derived: overall health, physical activities, development, discomfort, moods and temperaments, perceptions of current past and future health and perception of changes. Each scale score ranges from 0 (worst possible) to 100 (best possible).

    Measured: Baseline and Weeks 24, 52

  34. Change From Baseline to Week 24 and 52 in ITQoL SF-47 - Pain Score

    The ITQoL SF-47 consisted of 47 individual items and was filled in by the child's parent. The individual items are based on Likert scales with either 5 responses (coded as 1 through to 5) or 4 responses (coded as 1 through to 4). From subsets of these coded values, 11 scales are derived: overall health, physical activities, development, discomfort, moods and temperaments, perceptions of current past and future health and perception of changes. Each scale score ranges from 0 (worst possible) to 100 (best possible).

    Measured: Baseline and Weeks 24, 52

  35. Change From Baseline to Week 24 and 52 in ITQoL SF-47 - Temperament and Moods Score

    The ITQoL SF-47 consisted of 47 individual items and was filled in by the child's parent. The individual items are based on Likert scales with either 5 responses (coded as 1 through to 5) or 4 responses (coded as 1 through to 4). From subsets of these coded values, 11 scales are derived: overall health, physical activities, development, discomfort, moods and temperaments, perceptions of current past and future health and perception of changes. Each scale score ranges from 0 (worst possible) to 100 (best possible).

    Measured: Baseline and Weeks 24, 52

  36. Change From Baseline to Week 24 and 52 in ITQoL SF-47 - Behaviour Score

    The ITQoL SF-47 consisted of 47 individual items and was filled in by the child's parent. The individual items are based on Likert scales with either 5 responses (coded as 1 through to 5) or 4 responses (coded as 1 through to 4). From subsets of these coded values, 11 scales are derived: overall health, physical activities, development, discomfort, moods and temperaments, perceptions of current past and future health and perception of changes. Each scale score ranges from 0 (worst possible) to 100 (best possible).

    Measured: Baseline and Weeks 24, 52

  37. Change From Baseline to Week 24 and 52 in ITQoL SF-47 - General Health Score

    The ITQoL SF-47 consisted of 47 individual items and was filled in by the child's parent. The individual items are based on Likert scales with either 5 responses (coded as 1 through to 5) or 4 responses (coded as 1 through to 4). From subsets of these coded values, 11 scales are derived: overall health, physical activities, development, discomfort, moods and temperaments, perceptions of current past and future health and perception of changes. Each scale score ranges from 0 (worst possible) to 100 (best possible).

    Measured: Baseline and Weeks 24, 52

  38. Change From Baseline to Week 24 and 52 in ITQoL SF-47 - Change in Health Score

    The ITQoL SF-47 consisted of 47 individual items and was filled in by the child's parent. The individual items are based on Likert scales with either 5 responses (coded as 1 through to 5) or 4 responses (coded as 1 through to 4). From subsets of these coded values, 11 scales are derived: overall health, physical activities, development, discomfort, moods and temperaments, perceptions of current past and future health and perception of changes. Each scale score ranges from 0 (worst possible) to 100 (best possible).

    Measured: Baseline and Weeks 24, 52

  39. Change From Baseline to Week 24 and 52 in ITQoL SF-47 - Parent-Emotional Impact Score

    The ITQoL SF-47 consisted of 47 individual items and was filled in by the child's parent. The individual items are based on Likert scales with either 5 responses (coded as 1 through to 5) or 4 responses (coded as 1 through to 4). From subsets of these coded values, 11 scales are derived: overall health, physical activities, development, discomfort, moods and temperaments, perceptions of current past and future health and perception of changes. Each scale score ranges from 0 (worst possible) to 100 (best possible).

    Measured: Baseline and Weeks 24, 52

  40. Change From Baseline to Week 24 and 52 in ITQoL SF-47 - Parent-Time Impact Score

    The ITQoL SF-47 consisted of 47 individual items and was filled in by the child's parent. The individual items are based on Likert scales with either 5 responses (coded as 1 through to 5) or 4 responses (coded as 1 through to 4). From subsets of these coded values, 11 scales are derived: overall health, physical activities, development, discomfort, moods and temperaments, perceptions of current past and future health and perception of changes. Each scale score ranges from 0 (worst possible) to 100 (best possible).

    Measured: Baseline and Weeks 24, 52

  41. Change From Baseline to Week 24 and 52 in ITQoL SF-47 - Family Cohesion Impact Score

    The ITQoL SF-47 consisted of 47 individual items and was filled in by the child's parent. The individual items are based on Likert scales with either 5 responses (coded as 1 through to 5) or 4 responses (coded as 1 through to 4). From subsets of these coded values, 11 scales are derived: overall health, physical activities, development, discomfort, moods and temperaments, perceptions of current past and future health and perception of changes. Each scale score ranges from 0 (worst possible) to 100 (best possible).

    Measured: Baseline and Weeks 24, 52

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Nov 2013 (estimated)
  2. Study start25 Sep 2013
  3. Primary completion18 Dec 2015
  4. Study completion18 Dec 2015

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
23 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01981954
Sponsor's protocol ID
905-CL-074
Other IDs
2012-003178-22
Status last verified
Oct 2024
First submitted
6 Nov 2013
Last updated
31 Oct 2024
Data monitoring committee
Yes
Individual data sharing
No: Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

Publications

  • Tannenbaum S, den Adel M, Krauwinkel W, Meijer J, Hollestein-Havelaar A, Verheggen F, Newgreen D. Pharmacokinetics of solifenacin in pediatric populations with overactive bladder or neurogenic detrusor overactivity. Pharmacol Res Perspect. 2020 Dec;8(6):e00684. doi: 10.1002/prp2.684.

    PubMed 33231929
  • Franco I, Hoebeke P, Baka-Ostrowska M, Bolong D, Davies LN, Dahler E, Snijder R, Stroosma O, Verheggen F, Newgreen D, Bosman B, Vande Walle J. Long-term efficacy and safety of solifenacin in pediatric patients aged 6 months to 18 years with neurogenic detrusor overactivity: results from two phase 3 prospective open-label studies. J Pediatr Urol. 2020 Apr;16(2):180.e1-180.e8. doi: 10.1016/j.jpurol.2019.12.012. Epub 2019 Dec 27.

    PubMed 32007426

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Solifenacin succinate in people with Neurogenic Detrusor Overactivity and Pediatric, run by Astellas Pharma Europe B.V. at 8 sites in 6 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 31 Oct 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 8 sites in Poland, South Korea, United States, Belgium, Philippines and 1 more country. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 21 Jun 2018). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change From Baseline to Week 24 in Maximum Cystometric Capacity (MCC) (time frame: Baseline and Week 24). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01981954, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Oct 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in